soul trial oral semaglutide cardiovascular outcomes results 2024 nejm 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM Trial Scorecard: SOUL

Upgrade your health defense with Quercetin+ and start feeling more energized, resilient, and ready to take on each day.* Unlike standard quercetin, which often isnt well absorbed, our patented phytosome formula delivers 20x better absorption for faster, more effective immune system support, anti-inflammatory benefits, and aiding in cardiovascular, respiratory, and brain protection.* Quercetin+ is a game-changer for immune support and overall health

Ready for your jumpstart to a healthier, happier life

CQR300 , a Cissus quadrangularis extract, works at the gut level to inhibit the enzymes responsible for fat and carbohydrate digestion, reducing caloric uptake

Rajesh Dhirmalani, Replenza Advisory Board Member Expert Backing : Replenza is developed with the guidance of a board of experts, including: Dr

Proteomic analysis was performed to identify differentially expressed proteins (DEPs), while metabolomic profiling was used to characterize metabolic changes

People who took GLP-1s for an average of three years without stopping saw the biggest heart health benefits